Analyst firms · Robert W. Baird · RMD
Robert W. Baird RMD price target and rating history
ResMed Inc. (RMD) · Health Care
Robert W. Baird rates ResMed Inc. (RMD) Neutral with a $275 price target, as of its latest action on Dec 16, 2025. It has published 4 rating actions on RMD since January 2022, including 2 upgrades and 1 downgrade. Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Robert W. Baird's $275 is 17% above that.
- Current rating
- Neutral
- Price target
- $275
- Median target, all firms
- $235
- Actions on RMD
- 4
Robert W. Baird price target on RMD
Every Robert W. Baird rating on RMD
- Dec 16, 2025
- Sep 24, 2024
- Jan 13, 2022
- Jan 13, 2022
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about Robert W. Baird and RMD
- What is Robert W. Baird's price target for RMD?
- Robert W. Baird's latest stated price target for ResMed Inc. (RMD) is $275, from its action on Dec 16, 2025.
- What is Robert W. Baird's rating on RMD?
- Robert W. Baird rates RMD Neutral, a neutral rating, as of Dec 16, 2025.
- When did Robert W. Baird last change its view on RMD?
- On Dec 16, 2025, Robert W. Baird downgrades to Neutral from Outperform, price target $275.
- How does Robert W. Baird's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Robert W. Baird's $275 is 17% above that.
More RMD rating histories
- RBC Capital Markets13
- Citigroup8
- Morgan Stanley4
- CLSA5
- Wolfe Research3
- Needham3
- J.P. Morgan6
- BofA Securities3
All Robert W. Baird ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.